Search Demo - PsychoGenics



Services
- THERAPEUTIC AREAS
- CAPABILITIES
In Vivo AI Platforms
News & Insights
- News
  - Press Releases
  - Upcoming Events
- Insights
About
Contact Us

Filters

Therapeutic Areas

Drug Abuse Liability Quality

In Vivo AI Platforms

eCube SmartCube NeuroCube PhenoCube

Biomarker Bioanalysis

Mental Illness

Anxiety Depression Schizophrenia

Neurodegenerative Disorders

Alzheimer’s Disease Amyotrophic Lateral Sclerosis Huntington’s Disease Parkinson’s Disease Spinal Muscular Atrophy

Neurodevelopmental Disorders

Autism Spectrum Disorder Rett Syndrome

Neuromuscular Disorders

Amyotrophic Lateral Sclerosis Charcot-Marie-Tooth Spinal Muscular Atrophy

Pain

Acute Pain Inflammatory Pain Neuropathic Pain Osteoarthritis Pain Postoperative Pain PSPP Program Visceral Pain

Sleep & Seizure Disorders

Epilepsy Rett Syndrome Seizure Tuberous Sclerosis Complex

Rare CNS Disorders

Charcot-Marie-Tooth Fragile X Syndrome Gaucher Disease Rett Syndrome Tuberous Sclerosis Complex

Spinal Cord Injury

Traumatic Brain Injury

Spinal Cord Injury TBI

Specific Disorders

Alzheimer’s Disease Amyotrophic Lateral Sclerosis Huntington’s Disease Parkinson’s Disease Spinal Muscular Atrophy ADHD Studies Angelman Syndrome Autism Spectrum Disorder Fragile X Syndrome Rett Syndrome Amyotrophic Lateral Sclerosis Charcot-Marie-Tooth Duchenne Muscular Dystrophy Spinal Muscular Atrophy Angelman Syndrome Charcot-Marie-Tooth Dravet Syndrome Fragile X Syndrome Gaucher Disease Rett Syndrome Tuberous Sclerosis Complex

Apply Filters

Filters

All News Press Releases Upcoming Events Publications Posters Research Updates

PRESS RELEASES

PsychoGenics Appoints Dr. Stephen Morairty as Vice President, Translational Neuroscience and Jean-Sebastien Valois as Vice President, Engineering and AI Development

December 14, 2021

PUBLICATION

Elevation of brain magnesium with Swiss chard and buckwheat extracts in an animal model of reduced magnesium dietary intake

November 4, 2021

WEBINAR

Use of Phenotypic Screening in Mice in the Development of a Novel Non-D2-Receptor-Targeting Drug for the Treatment of Schizophrenia

December 9, 2020

PUBLICATION

Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex

October 8, 2020

Items per page:

←01…23 242526 27…39 Next →

Let’s Find the Right Solution Together

Our scientists are here to help you find the right model or capability for your program.

Request a Consultation

Quick Links

Services
In Vivo AI Platforms
News & Insights
About
Contact

Contact

Address

215 College Road Paramus, NJ 07652

Email

info@psychogenics.com

Phone

(914) 406-8019

Fax

(914) 406-8090

Privacy Policy
Terms of Use
Financial Conflict of Interest Policy
Sitemap
Webmaster

Manage Consent

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Functional Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage options
Manage services
Manage {vendor_count} vendors
Read more about these purposes

View preferences

{title}
{title}
{title}

Manage Consent

Functional Functional Always active

Preferences Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics Statistics

Marketing Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage options
Manage services
Manage {vendor_count} vendors
Read more about these purposes

View preferences

{title}
{title}
{title}

Filters

Filters

Therapeutic Areas

Specific Disorders

Filters

PsychoGenics Appoints Dr. Stephen Morairty as Vice President, Translational Neuroscience and Jean-Sebastien Valois as Vice President, Engineering and AI Development

Elevation of brain magnesium with Swiss chard and buckwheat extracts in an animal model of reduced magnesium dietary intake

Molecular Biomarkers and Disease Markers at PsychoGenics [WEBINAR]

PsychoGenics Chief Innovation Officer Honored for Scientific Excellence

Preclinical Seizure and Epilepsy [WEBINAR]

AI-driven Phenotypic Drug Discovery at PsychoGenics [WEBINAR]

Preclinical Mouse Models of Huntington’s Disease at PsychoGenics [WEBINAR]

Use of Phenotypic Screening in Mice in the Development of a Novel Non-D2-Receptor-Targeting Drug for the Treatment of Schizophrenia

Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex

Let’s Find the Right Solution Together